Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.
According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.
ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.
Airiver medical receives FDA approval for central airway stenosis trial
INOVIO to begin rolling submission of BLA for INO-3107
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
LivaNova announces commercial launch of Essenz Perfusion System in China
Precigen's PAPZIMEOS granted US FDA approval to treat with recurrent respiratory papillomatosis
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis